Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson ’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

ConclusionFoslevodopa/foscarbidopa has the potential to provide a safe and efficacious, individualized, 24-hour/day, nonsurgical alternative for patients with PD.Trial Registration NumberClinicalTrials.gov identifier NCT03781167.
Source: Neurology and Therapy - Category: Neurology Source Type: research